Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Oxygenta Pharma
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 8.19 | 6.86 | 13.08 | 9.15 | 10.55 | 12.62 | 14.01 | 33.21 | 49.47 | 15.13 | 14.30 | 33.93 | 49.61 |
| Expenses + | 10.44 | 10.50 | 15.06 | 11.63 | 12.17 | 14.40 | 16.18 | 37.57 | 51.15 | 21.96 | 18.87 | 38.01 | 49.49 |
| Operating Profit | -2.25 | -3.64 | -1.98 | -2.48 | -1.62 | -1.78 | -2.17 | -4.36 | -1.68 | -6.83 | -4.57 | -4.08 | 0.12 |
| OPM % | -27.47% | -53.06% | -15.14% | -27.10% | -15.36% | -14.10% | -15.49% | -13.13% | -3.40% | -45.14% | -31.96% | -12.02% | 0.24% |
| Other Income + | -0.05 | -0.13 | -0.03 | -0.02 | 0.26 | 0.02 | 0.75 | 0.49 | -0.22 | 0.16 | -0.06 | 0.00 | 0.17 |
| Interest | 0.94 | 0.29 | 0.34 | 0.36 | 0.59 | 0.41 | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 |
| Depreciation | 0.85 | 0.50 | 0.83 | 0.69 | 0.64 | 0.65 | 0.66 | 0.71 | -0.23 | 0.85 | 0.86 | 0.86 | -0.24 |
| Profit before tax | -4.09 | -4.56 | -3.18 | -3.55 | -2.59 | -2.82 | -2.77 | -4.97 | -3.80 | -8.15 | -6.44 | -6.33 | -1.28 |
| Tax % | 4.89% | 0.00% | -0.63% | 6.48% | -409.27% | -51.42% | 2.89% | -20.72% | -43.42% | -25.03% | -23.45% | -23.38% | 32.81% |
| Net Profit + | -4.29 | -4.56 | -3.16 | -3.78 | 8.02 | -1.36 | -2.85 | -3.93 | -2.15 | -6.11 | -4.93 | -4.84 | -1.70 |
| EPS in Rs | -3.02 | -1.36 | -0.94 | -1.13 | 2.40 | -0.38 | -0.80 | -1.06 | -0.58 | -1.65 | -1.33 | -1.31 | -0.46 |
Financials of Oxygenta Pharma
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 |
| Expenses + | 10 | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 128 |
| Operating Profit | -4 | -4 | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -15 |
| OPM % | -67% | -34% | -59% | -31% | -10% | -57% | 7% | 2% | -23% | -24% | -9% | -14% |
| Other Income + | 0 | 0 | 1 | 1 | 0 | 4 | 2 | 1 | -1 | 0 | 1 | 0 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 |
| Depreciation | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 2 |
| Profit before tax | -7 | -6 | -6 | -4 | -3 | -6 | 3 | -0 | -11 | -14 | -12 | -22 |
| Tax % | -11% | 0% | 2% | 1% | -7% | -3% | 7% | 24% | 2% | -75% | -16% | -21% |
| Net Profit + | -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 |
| EPS in Rs | -5.99 | -5.39 | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.62 | -4.75 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Oxygenta Pharma
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -26 | -32 | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -62 | -80 |
| Borrowings + | 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 110 |
| Other Liabilities + | 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 53 |
| Total Liabilities | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| Fixed Assets + | 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 40 | 48 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 44 | 72 |
| Total Assets | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
Financials of Oxygenta Pharma
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | -28 |
| Cash from Investing Activity + | 1 | -2 | -1 | -0 | -1 | -0 | -7 | -5 | -10 | -4 | -11 | -14 |
| Cash from Financing Activity + | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 9 | 43 |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 |
| Free Cash Flow | -7 | -1 | -0 | 1 | -8 | -3 | -8 | -7 | -11 | -17 | -9 | -41 |
| CFO/OP | 104% | -20% | -13% | -33% | 396% | 35% | -37% | -106% | 23% | 135% | -28% | 182% |
Financials of Oxygenta Pharma
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 | 32 |
| Inventory Days | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 | 105 |
| Days Payable | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 | 174 |
| Cash Conversion Cycle | -1,678 | -582 | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 | -37 |
| Working Capital Days | -616 | -454 | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 | -119 |
| ROCE % | -1% | -47% | -42% | -25% | -33% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…